

Assoc. Prof. NEŞE ÜNVER

Personal Information

Email: nese.unver@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/nese.unver>

Address: nese.unver@hacettepe.edu.tr

International Researcher IDs

ORCID: 0000-0002-4925-7179

ScopusID: 6602964709

Yoksis Researcher ID: 201671

Education Information

Post Doctorate, The University Of Texas Md Anderson Cancer Center, United States Of America 2013 - 2018

Doctorate, Hacettepe University, Kanser Enstitüsü, Temel Onkoloji Abd, Turkey 2008 - 2012

Postgraduate, Hacettepe University, Tıp Fakültesi, Tıbbı Bıyoloji Abd, Turkey 2006 - 2008

Dissertations

Doctorate, DENEYSEL AKCİĞER KANSERİ MODELİNDE CXCL7-ARACILI NÖTROFİL İNFİLTRASYONUNUN TÜMÖR GELİŞİMİ VE İMMÜNOLOJİSİ ÜZERİNE ETKİSİ, Hacettepe Üniversitesi, Kanser Enstitüsü, Temel Onkoloji Abd, 2012

Postgraduate, PSORİAZİSDE, PEROKSİZOM PROLİFERATÖRLERİ İLE AKTİVİTE OLAN RESEPTÖR BETA (PPAR BETA) GEN İFADESİNİN DÜZENLENMESİNDE ROL ALAN GEN İFADELERİNİN GERÇEK ZAMANLI POLİMERAZ ZİNCİR REAKSİYONU İLE ANALİZİ, Hacettepe Üniversitesi, Tıp Fakültesi, Tıbbı Bıyoloji Abd, 2008

Research Areas

Medicine, Health Sciences, Fundamental Medical Sciences, Immunology, Medical Biology, Life Sciences, Molecular Biology and Genetics, Molecular Biology of Cancer, Natural Sciences

Academic Titles / Tasks

Associate Professor, Hacettepe University, Kanser Enstitüsü, Temel Onkoloji A.B.D., 2024 - Continues

Associate Professor, Hacettepe University, Çocuk Sağlığı Enstitüsü, Pediatrik Ve Perinatal Patolojileri Araştırmaları A.B.D., 2022 - 2024

Assistant Professor, Hacettepe University, Çocuk Sağlığı Enstitüsü, Pediatrik Ve Perinatal Patolojileri Araştırmaları A.B.D., 2019 - 2024

Research Assistant, Hacettepe University, Kanser Enstitüsü, Temel Onkoloji A.B.D., 2009 - 2012

Advising Theses

Ünver N., Kanser hücrelerinin aşırı çoğalmasının yarattığı stres altında yardımcı T hücre yorulmasının incelenmesi, Doctorate, S.ULUSOY(Student), 2025

Ünver N., Özmen F., Pankreas Kanseri Hücre Hattında TFAM Ekspresyon Düzeyinin Hücre Fonksiyonları Üzerine Etkisi, Postgraduate, C.NARİN(Student), 2022

Ünver N., Esendağlı G., İnsan makrofajlarında nitrik oksit sentaz 2 (NOS2) ifade ve aktivitesinin bazal benzeri meme kanseri hücrelerinden üretilen faktörler varlığında incelenmesi, Postgraduate, G.BİLİR(Student), 2022

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Dissection of pro-tumoral macrophage subtypes and immunosuppressive cells participating in M2 polarization.**
Sezginer O., Ünver N.
Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2024 (SCI-Expanded)
- II. **Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy approaches**
Unver N.
Clinical and Experimental Medicine, vol.23, no.7, pp.3171-3177, 2023 (SCI-Expanded)
- III. **Tailored modulation of stemness and drug resistance marker characteristics in K-Ras mutant lung cancer cells via PD-L1 gene suppression.**
Unver N., Tavukcuoglu E., Esendagli G.
Life sciences, vol.311, pp.121171, 2022 (SCI-Expanded)
- IV. **SRGN-Triggered Aggressive and Immunosuppressive Phenotype in a Subset of TTF-1-Negative Lung Adenocarcinomas.**
Tanaka I., Dayde D., Tai M. C., Mori H., Solis L. M., Tripathi S. C., Fahrman J. F., Ünver N., Parhy G., Jain R., et al.
Journal of the National Cancer Institute, vol.114, pp.290-301, 2022 (SCI-Expanded)
- V. **Revisiting CCL-type chemokines in breast cancer and its milieu: Prominent targetable chemokines, CCL8 and CCL21.**
Unver N.
Bioscience reports, vol.41, 2021 (SCI-Expanded)
- VI. **Identification of the dominant angiogenic CXCL class chemokines associated with non-small cell lung cancer via bioinformatics tools.**
Unver N.
Medical oncology (Northwood, London, England), vol.38, pp.68, 2021 (SCI-Expanded)
- VII. **Cancer stemness as a target for immunotherapy is shaped by pro-inflammatory stress.**
Unver N.
Current stem cell research & therapy, vol.16, pp.792-800, 2021 (SCI-Expanded)
- VIII. **Transcriptional splice variants of CD40 and its prognostic value in breast cancer.**
Ünver N., Yöyen E., Weber B., Esendağlı G.
Turkish journal of biology = Turk biyoloji dergisi, vol.44, pp.73-81, 2020 (SCI-Expanded)
- IX. **Macrophage chemoattractants secreted by cancer cells: Sculptors of the tumor microenvironment and another crucial piece of the cancer secretome as a therapeutic target.**
Unver N.
Cytokine & growth factor reviews, 2019 (SCI-Expanded)
- X. **IL22 Promotes &Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties.**
KHOSRAVI N., CAETANO M., CUMPIAN A., Ünver N., DE L. G. R. C., NOBLE O., DALIRI S., HERNANDEZ B., GUTIERREZ B., EVANS S., et al.
Cancer immunology research, vol.6, pp.788-797, 2018 (SCI-Expanded)
- XI. **IL-6 family cytokines: Key inflammatory mediators as biomarkers and potential therapeutic targets.**
Unver N., MCALLISTER F.
Cytokine & growth factor reviews, vol.41, pp.10-17, 2018 (SCI-Expanded)

- XII. **Reduced IL-6 levels and tumor-associated phospho-STAT3 are associated with reduced tumor development in a mouse model of lung cancer chemoprevention with myo-inositol.**
Unver N., Delgado O., Zeleke K., Cumpian A., Tang X., Caetano M., Wang H., Katayama H., Yu H., Szabo E., et al.
International journal of cancer, vol.142, pp.1405-1417, 2018 (SCI-Expanded)
- XIII. **Investigation of hemophagocytic lymphohistiocytosis in severe sepsis patients.**
HALACLI B., Unver N., HALACLI S., CANPINAR H., ERSOY E., OCAL S., GUC D., BUYUKASIK Y., TOPELI A.
Journal of critical care, vol.35, pp.185-90, 2016 (SCI-Expanded)
- XIV. **IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.**
CAETANO M., ZHANG H., CUMPIAN A., GONG L., Unver N., OSTRIN E., DALIRI S., CHANG S., OCHOA C., HANASH S., et al.
Cancer research, vol.76, pp.3189-99, 2016 (SCI-Expanded)
- XV. **CXCL7-induced macrophage infiltration in lung tumor is independent of CXCR2 expression: CXCL7-induced macrophage chemotaxis in LLC tumors.**
Unver N., ESENDAGLI G., YILMAZ G., GUC D.
Cytokine, vol.75, pp.330-7, 2015 (SCI-Expanded)
- XVI. **Molecular analysis of Chanarin-Dorfman syndrome (CDS) patients: Identification of novel mutations in the ABHD5 gene**
EMRE S., Unver N., EVANS S., YÜZBAŞIOĞLU A., GÜRAKAN F., GÜMRÜK F., KARADUMAN A.
EUROPEAN JOURNAL OF MEDICAL GENETICS, vol.53, no.3, pp.141-144, 2010 (SCI-Expanded)

Articles Published in Other Journals

- I. **In-Silico Analysis of The Correlation Between PD-L1 and Pro-Inflammatory Type Interleukins and The Distribution of Their Potential Primary Sources in KRAS-Mutated Non-Small Cell Lung Carcinoma**
Ünver N.
Acta Medica, vol.52, no.3, pp.189-196, 2021 (Peer-Reviewed Journal)
- II. **Regulatory Role of Chemerin in Lung Tumorigenesis and Cancer-associated Inflammation.**
Ünver N., Esendağlı G., Canpınar H., Güç D., Esendağlı G.
Acta Medica, vol.49, no.1, pp.16-25, 2018 (Peer-Reviewed Journal)

Books & Book Chapters

- I. **Mechanisms of Antitumor Immunity and Immunosurveillance**
Mohindroo C., Ünver N.
in: Cancer Immunoprevention, Florencia McAllister, Editor, Humana Press, Inc. , New Jersey, pp.1-6, 2022
- II. **Targets and Strategies for Cancer Immunoprevention**
Ünver N., Mohindroo C.
in: Cancer Immunoprevention, Florencia McAllister, Editor, Humana Press, Inc. , New Jersey, pp.7-17, 2022

Refereed Congress / Symposium Publications in Proceedings

- I. **Desmin and LaminB: Proteomic Analysis of Binding Partners of Two Differently Positioned Proteins**
Kural Mangıt E., Ünver N., Dinçer P. R.
3. Ulusal Proteomik Kongresi, İstanbul, Turkey, 27 February 2020, pp.13
- II. **Myo-inositol modulates the tumor microenvironment in a mouse model of lung cancer chemoprevention**

Unver N., Zeleke K. T., Tang X., Holt S., Moghaddam S. J. M., Wang H., Wistuba I. I., Hanash S. M., Ostrin E. J.
AACR 107th Annual Meeting on Bioinformatics and Systems Biology, Louisiana, United States Of America, 16 - 20
April 2016, vol.76

III. **Functional analysis of neutrophils cultured in supernatant of CXCL7 overexpressing lung cancer cells**

ÜNVER N., ESENDAĞLI G., GUC D.

European Congress of Immunology, Glasgow, United Kingdom, 5 - 08 September 2012, vol.137, pp.608

Supported Projects

ÜNVER N., ESENDAĞLI G., ULUTÜRK S., Project Supported by Higher Education Institutions, Aspirin varlığında IFN γ ile uyarılmış PDL1 ekspresyonuna sahip küçük hücreli olmayan akciğer kanseri hücre sekretomunun makrofaj polarizasyonu üzerine etkisi, 2021 - Continues

Unver N., Atasoy S., Omurtag Özgen P. S., Dağ A., TUBITAK Project, Polimer-Monoklonal Antikor Konjugatı Kullanılarak Makrofajlarda Membran Modifikasyonunun Gerçekleştirilmesi ve İmmünoterapötik Etkinliğinin Değerlendirilmesi, 2024 - 2026

ÖZMEN F., ESENDAĞLI G., KOCATÜRK B., ÜNVER N., CANPINAR H., GÜNAYDIN G., Project Supported by Higher Education Institutions, Kanser Biyolojisi ve İmmünolojisi Alanında Temel Onkoloji Araştırmaları, 2022 - 2024

Unver N., Esendağlı G., Taşkiran Z. E., Kankılıç T., Aerts Kaya F. S. F., Öztürk S. C., Öztürk S. E., TUBITAK Project, Körfare (Nannospalax) fibroblast ve mezenkimal kök hücrelerinde karsinogenez dirençliliğinin araştırılması ve transkriptomik imzanın keşfi, 2022 - 2024

ÜNVER N., ESENDAĞLI G., Tavukçuoğlu E., Project Supported by Higher Education Institutions, K-Ras mutant akciğer kanserinde, PD-L1 gen ekspresyonunun siRNA aracılı baskılanmasının kanser kök hücre ve ilaç dirençliliği belirteçleri üzerine etkisi, 2020 - 2023

ÖZMEN F., ÜNVER N., Narin C., Project Supported by Higher Education Institutions, Pankreas Hücre Hatlarında TFAM Ekspresyon Düzeyinin Hücre Fonksiyonları Üzerine Etkisi, 2021 - 2022

Esendağlı G., Öztürk S. C., Karataş Kurşun H., Çetin E., Gökşen S., Tel B. C., Ünver N., Erol T., Project Supported by Higher Education Institutions, Deneysel hayvan çalışmalarına yönelik bilimsel işleyiş platformlarının oluşturulması ve sınanması, 2021 - 2022

Metrics

Publication: 23

Citation (WoS): 441

Citation (Scopus): 488

H-Index (WoS): 9

H-Index (Scopus): 9

Awards

ÜNVER N., FEN FAKULTESİ BİRİNCİLİĞİ, HACETTEPE UNIVERSİTESİ, June 2005

Non Academic Experience

University, The University of Texas MD Anderson Cancer Center, Department of Clinical Cancer Prevention-Research